Competitive intel brief on a Phase II readout
Four agents turn a rival's trial data into a defensible brief.
Open the live lab · preloaded to this scenario
Multiagent Orchestration Economics Board
Context
A pharma competitive intelligence team must brief leadership on a rival's Phase II readout within 48 hours. A researcher pulls the trial registry, press, and KOL commentary; an analyst reconciles the reported endpoints against the label ambition; a medical writer drafts; and a regulatory critic checks every claim against what the data actually supports.
The decision
Multiagent is worth the multiple only for high stakes synthesis like this, where a wrong read moves a portfolio decision. Routine literature scans stay single agent.
What most miss
The regulatory critic is the difference between 'intel' and 'a claim our own medical team can't defend.' Speed without the critic manufactures confident errors.
Stakes
A misread efficacy signal can misdirect a go/no go on a program worth hundreds of millions.
Studied · Agent Architecture and Protocol Strategy Artifacts · verified 2026-07-03
Sources: Clinical-trial reporting norms, ClinicalTrials.gov, Phase II endpoint conventions; Pharma competitive-intelligence workflow patterns (registry + KOL synthesis)